| 1 |
Chun SG, Hu C, Choy H, et al. Impact of intensity-modulated radiation therapy technique for locally advanced non-smallcell lung cancer: a secondary analysis of the NRG Oncology RTOG 0617 randomized clinical trial. J Clin Oncol 2017;35:56-62./
|
|
| 2 |
Tam K, Daly M, Kelly K. Treatment of locally advanced non-small cell lung cancer. Hematol Oncol Clin North Am 2017;31:45-57./
|
|
| 3 |
Brandner ED, Chetty IJ, Giaddui TG, Xiao Y, Huq MS. Motion management strategies and technical issues associated with stereotactic body radiotherapy of thoracic and upper abdominal tumors: a review from NRG oncology. Med Phys 2017;44:2595-612./
|
|
| 4 |
Koide Y, Kodaira T, Tachibana H, et al. Clinical outcome of definitive radiation therapy for superficial esophageal cancer. Jpn J Clin Oncol 2017;47:393-400./
|
|
| 5 |
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: breast cancer (version 2.2016) [Internet]. Fort Washington, PA: National Comprehensive Cancer Network; c2017 [cited 2017 Jun 1]. Available from: https://www.nccn.org/professionals/physician_gls/f_guidelines.asp./
|
|
| 6 |
Morris WJ, Tyldesley S, Rodda S, et al. Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): an analysis of survival endpoints for a randomized trial comparing a low-dose-rate brachytherapy boost to a dose-escalated external beam boost for high- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys 2017;98:275-85./
|
|
| 7 |
Rodda S, Tyldesley S, Morris WJ, et al. ASCENDE-RT: an analysis of treatment-related morbidity for a randomized trial comparing a low-dose-rate brachytherapy boost with a doseescalated external beam boost for high- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys 2017;98:286-95./
|
|
| 8 |
Rodda S, Morris WJ, Hamm J, Duncan G. ASCENDE-RT: an analysis of health-related quality of life for a randomized trial comparing low-dose-rate brachytherapy boost with doseescalated external beam boost for high- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys 2017;98:581-9./
|
|
| 9 |
Fizazi K, Tran N, Fein L, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 2017;377:352-60./
|
|
| 10 |
McLaughlin PW, Liss AL, Nguyen PL, et al. ACR Appropriateness Criteria locally advanced, high-risk prostate cancer. Am J Clin Oncol 2017;40:1-10./
|
|